IBDEI0ZV ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16180,0)
 ;;=E87.5^^61^768^8
 ;;^UTILITY(U,$J,358.3,16180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16180,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,16180,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,16180,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,16181,0)
 ;;=E89.2^^61^768^30
 ;;^UTILITY(U,$J,358.3,16181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16181,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,16181,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,16181,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,16182,0)
 ;;=E89.6^^61^768^29
 ;;^UTILITY(U,$J,358.3,16182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16182,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,16182,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,16182,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,16183,0)
 ;;=L68.0^^61^768^6
 ;;^UTILITY(U,$J,358.3,16183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16183,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,16183,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,16183,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,16184,0)
 ;;=M80.00XA^^61^768^2
 ;;^UTILITY(U,$J,358.3,16184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16184,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,16184,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,16184,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,16185,0)
 ;;=M81.0^^61^768^3
 ;;^UTILITY(U,$J,358.3,16185,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16185,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,16185,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,16185,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,16186,0)
 ;;=M85.80^^61^768^26
 ;;^UTILITY(U,$J,358.3,16186,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16186,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,16186,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,16186,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,16187,0)
 ;;=N62.^^61^768^5
 ;;^UTILITY(U,$J,358.3,16187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16187,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,16187,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,16187,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,16188,0)
 ;;=E66.3^^61^768^27
 ;;^UTILITY(U,$J,358.3,16188,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16188,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,16188,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,16188,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,16189,0)
 ;;=E89.1^^61^768^31
 ;;^UTILITY(U,$J,358.3,16189,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16189,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,16189,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,16189,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,16190,0)
 ;;=R73.03^^61^768^33
 ;;^UTILITY(U,$J,358.3,16190,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16190,1,3,0)
 ;;=3^Pre-Diabetes
 ;;^UTILITY(U,$J,358.3,16190,1,4,0)
 ;;=4^R73.03
 ;;^UTILITY(U,$J,358.3,16190,2)
 ;;=^8295662
 ;;^UTILITY(U,$J,358.3,16191,0)
 ;;=E73.9^^61^768^18
 ;;^UTILITY(U,$J,358.3,16191,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16191,1,3,0)
 ;;=3^Lactose Intolerance,Unspec
 ;;^UTILITY(U,$J,358.3,16191,1,4,0)
 ;;=4^E73.9
 ;;^UTILITY(U,$J,358.3,16191,2)
 ;;=^5002914
 ;;^UTILITY(U,$J,358.3,16192,0)
 ;;=H40.9^^61^769^11
 ;;^UTILITY(U,$J,358.3,16192,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16192,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,16192,1,4,0)
 ;;=4^H40.9
